CNS Pharmaceuticals, Inc. (CNSP) Stock Price & Analysis
CNS Pharmaceuticals, Inc. (CNSP) closed at USD 5.18 on Thursday, October 15, 2026, down 3.23% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 5.35; the Oct 15, 2026 session ranged USD 5.18–5.18 on volume of 861 shares. Market capitalization is $7.57M, with a 52-week range of USD 1.9–10.54 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CNSP.md
Key facts (CNSP)
- Analysts: None (1 analysts), mean target USD 10 (range 10–10).
- Total return with dividends: 1Y -45.5% vs S&P 500 +18.1%; 5Y -100.0% vs S&P 500 +85.1%.
Analysts (CNSP)
Consensus None, 1 analysts; mean target USD 10 (low 10, high 10).
Total return (dividends reinvested) (CNSP)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -45.5% | -100.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -45.6% | -91.7% |
| Volatility (annualized) | 146.9% | 163.7% |
| Max drawdown | -77.6% (Oct 2025→Apr 2026) | -100.0% (Oct 2021→Apr 2026) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 5.18 |
|---|---|
| Change | ▼ 3.23% (down) |
| Previous Close | USD 5.35 |
| Open | USD 5.18 |
| Day Range | USD 5.18 – 5.18 |
| 52-Week Range | USD 1.9 – 10.54 |
| Volume | 861 shares |
| Market Cap | $7.57M |
| Exchange | NCM |
Technical Analysis (CNSP)
Nexqual's technical model rates CNSP "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.58 (neutral) |
| vs SMA50 | Below (USD 5.47) |
| MACD | -0.04 (negative) |
Analyst Ratings (CNSP)
Wall Street analysts rate CNSP "None" based on 1 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
Earnings (CNSP)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.38 vs est -0.24 ▼ miss |
| 2026-03-31 | USD -7.3 vs est -5.37 ▼ miss |
| 2025-12-31 | USD -10.15 vs est -5.09 ▼ miss |
| 2025-09-30 | USD -5.76 vs est -6.63 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (CNSP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -106.62% |
| Current Ratio | 5.87 |
| Total Cash | $19.98M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (CNSP)
Nexqual rates CNS Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $20M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$13M (TTM) |
| Efficiency | Critical — ROE -107%, ROA -58.0% |
Ownership (CNSP)
| Insider Ownership | +0.95% |
|---|---|
| Institutional Ownership | +21.25% |
| Shares Outstanding | 1.46M |
| Float | 1.32M |
| Short % of Float | +0.06% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (CNSP)
CNS Pharmaceuticals, Inc. is led by Rami Levin (age 56), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| President, CEO & Director | Rami Levin (age 56) |
|---|---|
| Chief Financial Officer | Steve O'Loughlin (age 40) |
| Chief Technology Officer | Eric Faulkner M.B.A., M.Sc. (age 52) |
Major Backers & Investors (CNSP)
Notable institutional backers of CNS Pharmaceuticals, Inc. include Ikarian Capital, LLC, Adar1 Capital Management, LLC , Stonepine Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 9.29% |
| Adar1 Capital Management, LLC | 4.79% |
| Stonepine Capital Management, LLC | 2.84% |
| Boothbay Fund Management, LLC | 0.93% |
| Fidelity | 0.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.66% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt